George A. Ricaurte | Academic Influence

George A. Ricaurte's AcademicInfluence.com Rankings

George A. Ricaurte

Medical

#798

World Rank

#1047

Historical Rank

#282

USA Rank

Neurology

#124

World Rank

#189

Historical Rank

#37

USA Rank

medical Degrees

Download Badge

Medical

George A. Ricaurte's Degrees

Bachelors Psychology University of Miami

Similar Degrees You Can Earn

Best Online Bachelor's in Psychology 2025

Why Is George A. Ricaurte Influential?

(Suggest an Edit or Addition)

According to Wikipedia, George A. Ricaurte is a neurologist and researcher who works at the Johns Hopkins School of Medicine in the Department of Neurology. Biography Ricaurte received his MD from Northwestern University Medical School and his Ph.D. from the University of Chicago.

(See a Problem?)

George A. Ricaurte's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Amphetamine: effects on catecholamine systems and behavior. (1993) (847)
Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. (1999) (823)
Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428 (1998) (607)
Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine (1980) (547)
Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study (1980) (506)
Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain (1982) (491)
Memory impairment in abstinent MDMA ("Ecstasy") users (1998) (376)
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys (1986) (374)
Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. (1985) (372)
Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans (1994) (337)
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals (2000) (311)
Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study (1999) (298)
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. (1988) (296)
Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. (1992) (273)
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. (1994) (272)
Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") (1995) (266)
Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers (1984) (234)
Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB (2005) (213)
Long-term effects of chronic methamphetamine administration in rhesus monkeys (1989) (205)
Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users (2008) (198)
(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies (2000) (197)
Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra (1987) (192)
Severe Dopaminergic Neurotoxicity in Primates After a Common Recreational Dose Regimen of MDMA ("Ecstasy") (2002) (186)
Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment (1986) (184)
Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 (1995) (171)
In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428 (1993) (169)
Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? (1992) (168)
Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine (“ecstasy”) users: relationship to cognitive performance (2008) (155)
Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine (1989) (151)
Positron emission tomography of striatal serotonin transporters in Parkinson disease. (2003) (145)
Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate (1980) (144)
Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. (1991) (140)
Amphetamine neurotoxicity: accomplishments and remaining challenges (2004) (137)
Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. (1993) (136)
Neurotoxic Amphetamine Analogues: Effects in Monkeys and Implications for Humans a (1992) (135)
Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ‘Ecstasy’) (1996) (132)
Recognition and management of complications of new recreational drug use (2005) (131)
Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). (2000) (123)
Persistent effects of (+/- )3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. (1993) (122)
Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations a (1990) (122)
Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum (1985) (115)
Effect of Temperature on Dopamine Transporter Function and Intracellular Accumulation of Methamphetamine: Implications for Methamphetamine-Induced Dopaminergic Neurotoxicity (2000) (111)
Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys (2004) (111)
Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions (2002) (108)
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. (1997) (104)
Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. (1989) (96)
Neurochemical similarities between d,l-cathinone and d-amphetamine. (1982) (91)
Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. (1994) (90)
Loss of Serotonin Transporter Protein after MDMA and Other Ring-Substituted Amphetamines (2006) (87)
5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates (1988) (87)
In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine‐123 labeled RTI‐55 (1992) (87)
Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users (1999) (87)
Caveat Emptor: Editors Beware (2001) (81)
3,4-Methylenedioxymethamphetamine, serotonin and memory. (1993) (79)
Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand (1999) (79)
[123/125I]RTI‐55, an in vivo label for the serotonin transporter (1992) (78)
Neurotoxins, parkinsonism and Parkinson's disease. (1987) (77)
Pharmacokinetic Profile of Single and Repeated Oral Doses of MDMA in Squirrel Monkeys: Relationship to Lasting Effects on Brain Serotonin Neurons (2006) (75)
Older dopaminergic neurons do not recover from the effects of MPTP (1987) (75)
Amphetamine Treatment Similar to That Used in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder Damages Dopaminergic Nerve Endings in the Striatum of Adult Nonhuman Primates (2005) (74)
Dexfenfluramine neurotoxicity in brains of non-human primates (1991) (72)
MDMA (“Ecstasy”) and panic disorder: Induction by a single dose (1992) (71)
Cognitive Performance of MDMA-Treated Rhesus Monkeys: Sensitivity to Serotonergic Challenge (2002) (70)
Long‐term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine (2001) (67)
Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine (1983) (65)
Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. (1993) (65)
Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. (1996) (63)
Changes in Gene Expression Linked to Methamphetamine-Induced Dopaminergic Neurotoxicity (2002) (62)
Further Studies on the Role of Metabolites in (±)-3,4-Methylenedioxymethamphetamine-Induced Serotonergic Neurotoxicity (2009) (59)
Nerve terminal degeneration after a single injection of D-amphetamine in iprindole-treated rats: relation to selective long-lasting dopamine depletion (1984) (57)
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. (1987) (55)
Orally administered MDMA causes a long-term depletion of serotonin in rat brain (1988) (53)
Effects of (±) 3,4-Methylenedioxymethamphetamine (MDMA) on Sleep and Circadian Rhythms (2007) (52)
Repeated administration of MDMA causes transient down-regulation of serotonin 5-HT2 receptors (1992) (52)
Acquisition of MDMA self‐administration: pharmacokinetic factors and MDMA‐induced serotonin release (2014) (50)
Relationship between Temperature, Dopaminergic Neurotoxicity, and Plasma Drug Concentrations in Methamphetamine-Treated Squirrel Monkeys (2006) (48)
Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. (1992) (47)
Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomography ligand? (1990) (45)
Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. (2002) (44)
Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers (2009) (44)
Methylphenidate and brain dopamine neurotoxicity (1997) (44)
Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses (2008) (38)
Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons (1991) (38)
The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat (1991) (36)
Identification and Characterization of Metallothionein-1 and -2 Gene Expression in the Context of (±)3,4-Methylenedioxymethamphetamine-Induced Toxicity to Brain Dopaminergic Neurons (2004) (34)
A Murine Dopamine Neuron-Specific cDNA Library and Microarray: Increased COXI Expression during Methamphetamine Neurotoxicity (2001) (34)
Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. (2000) (34)
Use of MDMA and Other Illicit Drugs by Young Adult Males in Northern Spain (2002) (33)
The Effect of Catecholamine Depletion by Alpha-Methyl-Para-Tyrosine on Measures of Cognitive Performance and Sleep in Abstinent MDMA Users (2007) (32)
"Ecstasy" and serotonin neurotoxicity: new findings raise more questions. (2001) (31)
Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA) (1992) (30)
Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neurotoxic effects: importance of dose, species and drug. (1997) (30)
Direct Comparison of (±) 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Disposition and Metabolism in Squirrel Monkeys and Humans (2009) (29)
Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma. (2007) (29)
Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration (2002) (28)
Studies of (±)-3,4-Methylenedioxymethamphetamine (MDMA) Metabolism and Disposition in Rats and Mice: Relationship to Neuroprotection and Neurotoxicity Profile (2013) (27)
Assessing long-term effects of MDMA (Ecstasy) (2001) (27)
as Serotonin Transporter Radioligands Under Various Experimental Conditions (2002) (27)
Increased dopamine metabolism in the rat neostriatum after toxic doses of d-methylamphetamine (1983) (26)
The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age (1988) (26)
Dopamine transporter changes in neuropsychiatric disorders. (1998) (24)
Non-linear Pharmacokinetics of MDMA ( “ Ecstasy ” ) and its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA that Develop After Typical Psychoactive Doses (2008) (23)
Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. (1989) (23)
Thalamic hemorrhage with neglect and memory disorder (1986) (22)
Erratum: SEVERE dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy") (Science (2002) 297 (2260)) (2003) (22)
Effects of MDMA on blood glucose levels and brain glucose metabolism (2007) (22)
Experimental studies on 3,4-methylenedioxymethamphetamine (MDMA, “ECSTASY”) and its potential to damage brain serotonin neurons (2009) (21)
1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1987) (21)
REVIEW ■ : Long-lasting Effects of Recreational Drugs of Abuse on the Central Nervous System (1997) (19)
Altered sensitivity to d-methylamphetamine, apomorphine, and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine (2004) (18)
Hydrolysis of 3,4-methylenedioxymethamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma (2009) (18)
Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxymethamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasm (2009) (18)
Modulating role of dopamine on anesthetic requirements (1990) (17)
[3H]3,4-methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper. (1987) (17)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient. (1985) (17)
MDMA ("Ecstasy") and Neurotoxicity (2003) (16)
Modulating role of dopamine on anesthetic requirements. (1988) (16)
Dopamine is not essential for the development of methamphetamine-induced neurotoxicity (2010) (16)
The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age (1989) (16)
Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys. (1990) (16)
Altered prolactin response to M‐chlorophenylpiperazine in monkeys previously treated with 3,4‐methylenedioxymethamphetamine (MDMA) or fenfluramine (2002) (15)
Evaluation of the neurotoxic potential of N,N-dimethylamphetamine: an illicit analog of methamphetamine (1989) (15)
Fenfluramine's appetite suppression and serotonin neurotoxicity are separable. (1995) (14)
Dexfenfluramine and neurotoxicity (1992) (14)
Sleep Deprivation Differentially Impairs Cognitive Performance in Abstinent Methylenedioxymethamphetamine (“Ecstasy”) Users (2009) (14)
MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. (2002) (13)
Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine (1998) (13)
Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats (2013) (13)
Heating induces aggregation and decreases detection of serotonin transporter protein on western blots (2007) (12)
Metabolism and Disposition of 3,4-Methylenedioxymethamphetamine (“Ecstasy”) in Baboons after Oral Administration: Comparison with Humans Reveals Marked Differences (2011) (11)
Prolactin response to fenfluramine is independent of serotonin release. (1996) (11)
Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations. (2013) (11)
Acute poisoning with amphetamines (MDEA) and heroin: Antagonistic effects between the two drugs (1996) (11)
Subcortical aphasia revisited (1987) (11)
Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users (2011) (10)
Retraction (2003) (9)
Effects of MDMA on the Human Nervous System (2014) (9)
Motor dynamics encoding in the rostral zone of the cat cerebellar flocculus during vertical optokinetic eye movements (2000) (9)
Identifying the serotonin transporter signal in Western blot studies of the neurotoxic potential of MDMA and related drugs (2011) (9)
Chronic idiopathic ataxic neuropathy: neuropathology of a case (1989) (9)
Liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in rat brain. (2008) (9)
N-Methylation dissociates methamphetamine's neurotoxic and behavioral pharmacologic effects (1997) (8)
Further Studies on the Role of Metabolites in MDMA-induced Serotonergic Neurotoxicity (2009) (8)
Drug abuse and dependence: hazards and consequences of heroin, cocaine and amphetamines (2000) (7)
Neuropathology of cocaine abuse (1999) (6)
On the neurotoxicity of MDMA and related amphetamine derivatives. (1995) (6)
Behavioral Effects and Pharmacokinetics of (±)-3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) after Intragastric Administration to Baboons (2013) (6)
The effect of N-methylation on fenfluramine's neurotoxic and pharmacologic actions (1997) (5)
Pharmacokinetic and pharmacodynamic analysis of d-amphetamine in an attention task in rodents (2018) (5)
Strategies for detecting subclinical monoamine depletions in humans. (1993) (5)
Synthesis and neurotoxicity profile of 2,4,5-trihydroxymethamphetamine and its 6-(N-acetylcystein-S-yl) conjugate. (2011) (5)
Reinforcing effects of enantiomers of N,N-dimethylamphetamine in squirrel monkeys (2005) (5)
Effect of Glucoprivation on Serotonin Neurotoxicity Induced by Substituted Amphetamines (2002) (4)
Response to O'Shea and Colado: the MDMA neurotoxicity profile might provide clues to mechanisms. (2003) (4)
Direction-dependent distortions of retinocentric space in the visuomotor transformation for pointing (2000) (4)
Loss of Serotonin Transporter Protein after MDMA and Other Ring-Substituted Amphetamines (2008) (3)
ULTRASTRUCTURE OF NERVE CELL DEGENERATION IN THE SUBSTANTIA NIGRA IN EXPERIMENTAL MPTP-INDUCED PARKINSONISM IN THE MOUSE AND IN THE SQUIRREL MONKEY (1986) (3)
Fluoxetine increases the anorectic and long‐term dopamine‐depleting effects of phentermine (2000) (3)
MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Brendon P. Boot, Annis O. Mechan, Una D. McCann, George A. Ricaurte [Eur. J. Pharmacol. 453 (2002) 239-244]. (2004) (2)
POSITRON EMISSION TOMOGRAPHY FINDINGS IN HEAVY USERS OF MDMA. AUTHORS' REPLY (1999) (2)
Chapter 38 – Neuropsychiatric Complications of Substance Abuse (2008) (2)
Assessment of serotonergic inervation with MCN5652/PET Validation of kinetic models in baboons (1999) (2)
Erratum: 3,4-Methylenedioxymethamphetamine, serotonin and memory (Journal of Pharmacology and Experimental Therapeutics (1993) 266 (1097-1105)) (1994) (1)
Recent advances in addiction research (2001) (1)
Responses to i.v. L-tryptophan in MDMA users. (1989) (1)
Neuroimaging of MDMA-Induced Neurotoxicity (2002) (1)
Retraction notice to "MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities" [Eur. J. Pharmacol. 453 (2002) 239-244]. (2006) (1)
Dr Lewis S Seiden, 1934–2007 (2008) (0)
Sex differences of MDMA metabolism in squirrel monkeys: A comparison to findings in humans (2014) (0)
SUBSTITUTED PHENETHYLAMINE NEUROTOXICITY: STUDIES IN ANIMALS AND HUMANS (1992) (0)
lene dioxy a m p hetami n e ( M D A ) do n o t mediate its toxic effects on brain serotonin neurons (2001) (0)
Reply: MDMA and the Loss of Reinforcement in Fantegrossi et al (2004) (2004) (0)
Erratum: Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity (Neuroreport 9:12 (2691-2695)) (2000) (0)
Hepatitis C: bad news for substance misusers (0)
For personal use. Only reproduce with permission from The Lancet Publishing Group. Use of food-challenge tests in children (2001) (0)
FUNCTIONAL CONSEQUENCES OF MDMA NEUROTOXICITY: RELATION TO BRAIN SEROTONIN (1998) (0)
Discriminative‐stimulus effects of 3,4‐methylenedioxy‐N‐methylamphetamine (MDMA) and a novel MDMA quatenary analog (2013) (0)
Sleep apnea in young abstinent recreational MDMA (“ecstasy”) consumers (2011) (0)
A comparison of models with and without dissociation of [11C]WIN35,428 in identifying changes in dopamine transporters (2006) (0)
Microsoft Word-75965117-file00 (2012) (0)
Overdose and Withdrawal in Drug Abuse (2006) (0)
Reduction of SERT binding in Ecstasy users: Reproducibility of PET studies (2007) (0)
[11C]WIN-35,428 PET Imaging Reveals Decreased Dopamine Transporter Density in Abstinent Methamphetamine Users (1998) (0)
1st European Conference PAIMM 2001: Care Programs for Health Professionals with Mental Disorders and/or Addiction Behaviours in Europe (2002) (0)
Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay discounting in rats (2013) (0)
Dopamin receptors, transporters, and amphetamine-induced release in late middle life (2006) (0)
Analysis of the effects of deep brain stimulation in a mathematical model of coupled excitatory and inhibitory neural populations { (2017) (0)
Erratum: Effects of 7-nitroindazole on body temperature... (NeuroReport 9:12 (2691-2695)) (1998) (0)

This paper list is powered by the following services:

Other Resources About George A. Ricaurte

en.wikipedia.org

What Schools Are Affiliated With George A. Ricaurte?

George A. Ricaurte is affiliated with the following schools: